{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Number of participants alive 1 year post transplant.","groups":[{"description":"GVHD PROPHYLAXIS: All patients receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover.\n\nAnti-Thymocyte Globulin: Given IV\n\nBusulfan: Given IV\n\nClofarabine: Given IV\n\nFilgrastim-sndz: Given SC\n\nFludarabine: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nRituximab: Given IV\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo total body irradiation\n\nUmbilical Cord Blood Transplantation: Undergo cord blood transplant","id":"OG000","title":"Chemotherapy Plus Cord Blood Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant died 5 months post transplant.","reportingStatus":"POSTED","timeFrame":"Up to 12 months after transplant","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}